Veru Sells FC2 Condom Business For $18 Million, Focuses On Biopharma Pipeline
Veru Inc. (NASDAQ:VERU) shares jumped on Tuesday after the company disclosed the sale of its FC2 Female Condom (Internal ...
Biopharma company to cut 90% of its jobs after sale
A clinical stage biopharma firm in Miami is slashing its headcount after selling its female condom business to an investment ...
Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...
Veru sells FC2 Female Condom business for $18M
Veru (VERU) has sold its FC2 Female Condom business to clients managed by Riva Ridge Capital Management as well as other co-investors, for ...
Nasdaq9d
Veru Inc. Sells FC2 Female Condom Business for $18 Million to Focus on Biopharmaceutical Drug Development
Veru Inc. announced the sale of its FC2 Female Condom® business for $18 million to Riva Ridge Capital Management and co-investors. This trial evaluates enobosarm's safety and efficacy in ...
AOL9d
Veru Sells FC2 Condom Business For $18 Million, Focuses On Biopharma Pipeline
Veru Inc. (NASDAQ:VERU) shares jumped on Tuesday after the company disclosed the sale of its FC2 Female Condom (Internal Condom) business to clients managed by Riva Ridge Capital Management LP and ...
Benzinga.com9d
Veru Sells FC2 Condom Business For $18 Million, Focuses On Biopharma Pipeline
Veru sells its FC2 Female Condom business for $18M, shrinking its workforce by 90%, and refocusing on biopharma R&D. Proceeds will fund late-stage clinical trials, including enobosarm for improved ...
Morningstar9d
Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business
We are expecting topline clinical results for this study in January 2025.” As a result of the sale of the FC2 business, including the transfer of its UK and Malaysian based subsidiaries ...